Comparison of PLK2-low PDX lines to PLK2-high PDX lines when log2 fold change of control groups reached 2.5 suggested that volasertib has a better tumor growth–inhibitory effect in PLK2-low PDX lines (Fig. 5E–I). Here, PLK2 is linked to neoplasm.